IceCure Medical (NASDAQ:ICCM – Get Free Report) and Nyxoah (NASDAQ:NYXH – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.
Profitability
This table compares IceCure Medical and Nyxoah’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
| Nyxoah | -443.16% | -178.90% | -81.83% |
Analyst Recommendations
This is a summary of recent recommendations for IceCure Medical and Nyxoah, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 2 | 0 | 3 | 0 | 2.20 |
| Nyxoah | 1 | 1 | 2 | 0 | 2.25 |
Insider and Institutional Ownership
0.6% of IceCure Medical shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares IceCure Medical and Nyxoah”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.38 million | 2.26 | -$15.06 million | ($8.52) | -0.26 |
| Nyxoah | $11.33 million | 5.54 | -$101.92 million | ($2.52) | -0.64 |
IceCure Medical has higher earnings, but lower revenue than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
IceCure Medical has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
